Extended-Release

The warning, which could come soon, concerns UCB Inc. 's Tussionex Pennkinetic Extended-Release Suspension, which contains hydrocodone, a narcotic also used as a pain reliever.

FDA Will Issue Warning 2008

/PRNewswire/ -- Perrigo Company NASDAQ: PRGO; TASE announced today that the United States District Court for the Western District of Michigan has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex® tablets.

unknown title 2012

InPlay: Perrigo announced that the United States District Court for the Western District of Michigan has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets

unknown title 2012

Florida has ruled that Watson's generic versions of Mucinex®, Mucinex® D and Mucinex® DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and Pseudoephedrine/Guaifenesin) Extended-Release products, do not infringe U.S. Patent No. 6,372,252 (the "'252 Patent").

unknown title 2011

(NYSE AMEX: LCI) today announced the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg, representing the fourth product approval the company has received in the last five weeks.

unknown title 2011

Mucinex® Guaifenesin Extended-Release Tablets, 600 mg, an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately

unknown title 2012

Mucinex® Guaifenesin Extended-Release Tablets, 600 mg, an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $146 million through food, drug and mass merchandisers for the last 12 months, as measured by Information Resources, Inc.

unknown title 2011

Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg, are therapeutically equivalent to the reference listed drug, Ionamin

unknown title 2011

Nov. 28, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg.

unknown title 2011

"Recognizing the struggle that many have with losing weight, we are pleased to offer Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg base, which further rounds out our portfolio of anti-obesity treatments," said Arthur P. Bedrosian, president and chief executive officer of Lannett.

unknown title 2011